Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study

H. Horinouchi, N. Nogami, H. Saka, M. Nishio, T. Tokito, T. Takahashi, K. Kasahara, Y. Hattori, E. Ichihara, N. Adachi, T. Sawada, T. Shimamoto, K. Noguchi, M. C. Pietanza, T. Kurata

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)ii56-ii57
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - Apr 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this